Besides its core focus on developing humanized antibody therapeutics for a variety of indications, Protein Design Labs Inc. has enjoyed a brisk business licensing its technology to companies interested in humanizing their own antibodies, with 29 licensees. Last week, however, the European Patent

EP 0451216 issued to PDLI in 1996 covering the technique of humanizing monoclonal antibodies and was opposed by 18 companies, said Robert Kirkman, vice president of business